stockrow
Friday 6 November 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024.
- Revenue
- +57.1%
- EPS
- −42.9%
- Free cash flow
- −22.4%
Quarter to September 2026, against a year earlier
7.19
0.09
+1.27%
Follow COCH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 4 | 3 |
+8 more TTM periods Free account |
| 564.62% | 214.32% | 400.01% | 184.92% | ||
| (189.84%) | (168.14%) | (139.91%) | (285.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
193.43% | (278.88%) | (171.16%) | 674.72% | |
Average Days of Receivables |
107.45 | 116.38 | 74.87 | 80.27 | |
Free Cash Flow per Share |
— | (2.09) | (2.98) | (7.90) | |
Free Cash Flow |
— | (21.71) | (20.54) | (18.38) | |
Capital Expenditures |
— | (0.18) | — | (0.18) | |
| Other line items | |||||
Cash ROIC |
0.00% | (94.47%) | (57.99%) | 218.32% | |
Accounts Receivable Turnover |
3.79 | 3.21 | 4.14 | 0.55 | |
Accounts Payable Turnover |
0.49 | 0.55 | 0.57 | 0.38 | |
Inventory Turnover |
0.66 | 0.63 | 0.61 | 0.54 | |
Average Days of Payables |
552.39 | 739.08 | 645.68 | 1,219.45 | |
Days of Inventory on Hand |
526.91 | 573.47 | 565.92 | 645.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,235.50% | 6,776.33% | 5,717.95% | 5,180.91% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 4,249.28% | 3,852.56% | 3,797.10% | |
Share Based Compensation of Revenue |
0.00% | 467.63% | 370.94% | 309.13% | |
Interest Coverage |
— | — | — | (14.01) | |
Operating CF/Net income |
0.00 | 0.76 | 0.73 | 0.64 | |
Depreciation/Fixed assets |
0.00 | 1.34 | 1.31 | 1.22 | |
Capex/Depreciation |
— | (0.14) | 0.00 | (0.14) | |
Revenue per Share |
0.00 | 0.02 | 0.03 | 0.10 | |
Operating CF per Share |
— | (2.07) | (2.98) | (7.82) | |
Capex per Share |
— | (0.02) | 0.00 | (0.08) | |
Capex to Sales |
0.00 | 0.86 | 0.00 | 0.74 |
Columns are period end dates · fundamentals updated 5 Nov 2026